315 related articles for article (PubMed ID: 3717303)
41. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
Dorfman DM; Shahsafaei A
Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibodies Ki-B3 and Leu-M1 discriminate giant cells of infectious mononucleosis and of Hodgkin's disease.
Fellbaum C; Hansmann ML; Parwaresch MR; Lennert K
Hum Pathol; 1988 Oct; 19(10):1168-73. PubMed ID: 3169725
[TBL] [Abstract][Full Text] [Related]
43. Expression of vimentin and epithelial membrane antigen in human malignant lymphomas.
Sarker AB; Akagi T; Yoshino T; Hoshida Y; Takahashi K; Horie Y
Acta Pathol Jpn; 1990 Aug; 40(8):581-7. PubMed ID: 2239313
[TBL] [Abstract][Full Text] [Related]
44. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
45. Enhanced staining for Leu M1 (CD15) in Hodgkin's disease using a secondary antibody specific for immunoglobulin M.
LeBrun DP; Kamel OW; Dorfman RF; Warnke RA
Am J Clin Pathol; 1992 Jan; 97(1):135-8. PubMed ID: 1345892
[TBL] [Abstract][Full Text] [Related]
46. Lymphocyte predominance Hodgkin's disease: a reappraisal based upon histological and immunophenotypical findings in relapsing cases.
Regula DP; Weiss LM; Warnke RA; Dorfman RF
Histopathology; 1987 Nov; 11(11):1107-20. PubMed ID: 3692445
[TBL] [Abstract][Full Text] [Related]
47. Characterization of Reed-Sternberg cells with granulocyte specific monoclonal antibody.
Memon GM; Alam SM
J Pak Med Assoc; 1993 Feb; 43(2):32-4. PubMed ID: 8497101
[TBL] [Abstract][Full Text] [Related]
48. p53 expression in Reed-Sternberg cells of Hodgkin's disease.
Gupta RK; Norton AJ; Thompson IW; Lister TA; Bodmer JG
Br J Cancer; 1992 Oct; 66(4):649-52. PubMed ID: 1419601
[TBL] [Abstract][Full Text] [Related]
49. Characterization of a cell surface molecule expressed on B-lymphocytes and Hodgkin's cells.
Imam A; Stathopoulos E; Holland SL; Epstein AL; Taylor CR
Cancer Res; 1990 Mar; 50(5):1650-7. PubMed ID: 1689214
[TBL] [Abstract][Full Text] [Related]
50. Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease.
Marafioti T; Mancini C; Ascani S; Sabattini E; Zinzani PL; Pozzobon M; Pulford K; Falini B; Jaffe ES; Müller-Hermelink HK; Mason DY; Pileri SA
Haematologica; 2004 Aug; 89(8):957-64. PubMed ID: 15339679
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous expression of activated lymphoid cell-associated and granulocytic cell-associated antigens on Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.
Abe M; Wachi E; Wakasa H
Pathol Res Pract; 1988 Aug; 183(4):418-24. PubMed ID: 3186542
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease.
Brown MS; Holden JA; Rahn MP; Perkins SL
Am J Clin Pathol; 1998 Jan; 109(1):39-44. PubMed ID: 9426516
[TBL] [Abstract][Full Text] [Related]
53. Localization of anti-Leu-M1 (CD15) binding sites in Hodgkin's disease by immunoelectron microscopic examination.
Taatjes DJ; Mount SL; Trainer TD; Tindle BH
Am J Clin Pathol; 1994 Feb; 101(2):140-8. PubMed ID: 8116567
[TBL] [Abstract][Full Text] [Related]
54. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
[TBL] [Abstract][Full Text] [Related]
55. B- and T-lymphocytes in Hodgkin's disease. An immunohistochemical study utilizing heterologous and monoclonal antibodies.
Forni M; Hofman FM; Parker JW; Lukes RJ; Taylor CR
Cancer; 1985 Feb; 55(4):728-37. PubMed ID: 3155642
[TBL] [Abstract][Full Text] [Related]
56. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma.
Timens W; Visser L; Poppema S
Lab Invest; 1986 Apr; 54(4):457-61. PubMed ID: 3083157
[TBL] [Abstract][Full Text] [Related]
57. An immunohistological study of the cellular constituents of Hodgkin's disease using a monoclonal antibody panel.
Abdulaziz Z; Mason DY; Stein H; Gatter KC; Nash JR
Histopathology; 1984 Jan; 8(1):1-25. PubMed ID: 6368356
[TBL] [Abstract][Full Text] [Related]
58. Lymph node architecture in Hodgkin's disease: evidence for the role of the composite nodule in nodular sclerosing Hodgkin's disease.
Van Parys G; De Wolf-Peeters C; van den Oord JJ; Desmet VJ
Hematol Oncol; 1987; 5(2):147-54. PubMed ID: 3596471
[TBL] [Abstract][Full Text] [Related]
59. Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's disease are probable dendritic cell malignancies.
Kennedy IC; Hart DN; Colls BM; Nimmo JC; Willis DA; Angus HB
Clin Exp Immunol; 1989 Jun; 76(3):324-31. PubMed ID: 2787713
[TBL] [Abstract][Full Text] [Related]
60. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
